title: [A multicenter clinical study on clinical effects of meglumine cyclic adenylate in treating patients with chronic pulmonary heart disease].
abstract: OBJECTIVE
  To observe the clinical effects of meglumine cyclic adenylate (MCA) in treating patients with chronic pulmonary heart disease.
  
  
  METHODS
  785 patients with chronic pulmonary heart disease were divided into two groups: MCA group and control group. Both groups of patients were treated with the same ordinary methods, but MCA was given in the MCA group. The period of treatment was 5-7 days. The degree of improvement in clinical symptoms, signs, ECG, pulmonary ventilation function and arterial blood gas analysis of the two groups before and after treatment were compared.
  
  
  RESULTS
  The rates of improvement in clinical symptoms and signs were 92.2% and 73.6% in MCA group and control group respectively. VC increased (426 +/- 123) ml and (313 +/- 145) ml respectively as compared with the values before the treatment. FEV(1) increased (134 +/- 54) ml and (95 +/- 55) ml, PEF increased (0.78 +/- 0.32) L/s and (0.47 +/- 0.32) L/s and PaO(2) increased (23.4 +/- 9.5) mm Hg and (17.3 +/- 10.4) mm Hg respectively. The rates of ECG improvement were 63.7% and 41.2% respectively. There was significant difference between the two groups (P < 0.01 and 0.05).
  
  
  CONCLUSIONS
  Significant therapeutic effects were obtained in treating patients of chronic pulmonary heart disease with respiratory and cardiac failure by using ordinary treatment measures combined with MCA injection.
authors.affiliation: Department of Respiratory Diseases, The Qilu Hospital, Shandong University, Jinan 250012, China.
authors.forename: D
authors.initials: D
authors.lastname: Wu
authors.forename: Y
authors.initials: Y
authors.lastname: Zhao
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
authors.forename: W
authors.initials: W
authors.lastname: Wang
authors.forename: R
authors.initials: R
authors.lastname: Xu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D000242:Cyclic AMP / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011660:Pulmonary Heart Disease / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: C058387:meglumine cyclic adenylate; D008536:Meglumine; D000242:Cyclic AMP